http://orcid.org/0000-0003-2433-0859
Figures
Abstract
Purpose
To determine the concordance rate between core needle biopsy/vacuum-assisted biopsy (CNB/VAB) and postoperative histopathology in B3 (lesions of uncertain malignant potential) and B5a (in situ) lesions found on mammograms or ultrasound.
Material and methods
2,029 consecutive biopsies performed over 10 years for patients who underwent mammograms or ultrasounds. For CNB 14G needle and for VAB 8G/10G needles were used. In all biopsies, we identified the age, BI-RADS®, histopathological biopsy results, B-category, nuclear grade for DCIS and postoperative histopathology results in B3 and B5a cases from the biopsy.
Results
The B-categories from CNB/VAB were as follows: B2 42.2 percent (n = 856), B3 4.5 percent (n = 91), B5a 5.7 percent (n = 115), and B5b 47.6 percent (n = 967). In the B3-category, 72/91 patients underwent surgical excision, with a concordance rate of 83.3 percent (n = 60/72) and a discordance rate of 16.7 percent (n = 12/72) to postoperative histopathology. From the discordant cases, 67.7 percent (n = 8/12) showed DCIS and 32.3 percent (n = 4/12) showed invasive breast cancer. The BIRADS of the discordant cases was 4b in 41.7 percent (n = 5/12) and 5 in 58.3 percent (n = 7/12). The PPVs for malignancy of B3 lesions were 0.21, with no statistical significance between subgroups. In the B5a-category, 101 of 115 patients underwent surgery in our hospital, with a concordance rate of 80.2 percent (n = 81/101) and a discordance rate of 19.8 percent (n = 20/101) to postoperative histopathology. From the discordant cases, 55 percent (n = 11/20) showed invasive breast carcinoma of no special type (NST).
Conclusion
Our concordance rate for B3 (83.3 percent) and B5a (80.2 percent) lesions in the biopsies to postoperative histopathology is matching to previously published literature. Surgical excision is our recommendation for lesions biopsied with a B3 category in the histopathology and a BIRADS category of (4b, 4c and 5). The PPVs for malignancy of B3 lesions showed no statistical significance between subgroups. Also, the nuclear grade of DCIS was not statistically significant in terms of upgrade into invasive breast cancer.
Citation: Elsharkawy M, Vestring T, Raatschen H-J (2020) A ten-year, single-center experience: Concordance between breast core needle biopsy/vacuum-assisted biopsy and postoperative histopathology in B3 and B5a cases. PLoS ONE 15(5): e0233574. https://doi.org/10.1371/journal.pone.0233574
Editor: Fernando Schmitt, University of Toronto, CANADA
Received: February 10, 2020; Accepted: May 7, 2020; Published: May 21, 2020
Copyright: © 2020 Elsharkawy et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: All relevant data are within the paper.
Funding: The author(s) received no specific funding for this work.
Competing interests: The authors have declared that no competing interests exist.
Introduction
In Europe, the female breast was the most common cancer site in 2018 (523,000 cases) [1]. Breast biopsies are commonly performed to evaluate mammographic or palpable findings that are of concern, and the majority reveal benign findings [2].
The breast imaging and data system (BI-RADS®) categorizes mammographic findings from 0 to 6 [3], with categories 4 (including a- low; b- moderate; and c- high suspicion of malignancy) and 5 requiring tissue biopsy. According to guidelines for non-operative diagnostic procedures and reporting in breast cancer screening, the histological results of core needle biopsy (CNB) and vacuum-assisted biopsy (VAB) are categorized from B1 to B5 [4]. The B1 and B2 categories respectively represent normal and benign lesions, while the B4 and B5 categories respectively represent suspicious and malignant lesions [4]. The B3 category comprise lesions with uncertain malignant potential. The B5 category is further subdivided into B5a, which comprise in-situ carcinomas and the B5b, which comprise the invasive carcinomas [4].
The B3 category represents a heterogeneous group of lesions (for example: atypical ductal hyperplasia, radial scar, papillary lesions, etc.) that may be associated with malignant disease requiring surgical intervention [5]. With the increasing use of mammographic screening, the detection rate of B3 lesions in patients who were previously asymptomatic has increased [6, 7]. This has resulted in breast surgery for ultimately benign final histopathological diagnoses [5]. The rate of B3 lesions in biopsies ranged from 3.8 percent to 9.2 percent in screening program or single institution [8–13]. El Sayed et.al found that B3 rate was 5 percent from all CNBs (20.001) in screening program over 10 years [14]. Weigel et al, reported a B3 rate of 15.1 percent in digital mammography screening over a period of 4 years [15]. Lee et al, found that the B3 rate was higher in screening program compared to symptomatic patients (7.3 percent vs 2 percent) [6].
Furthermore, ductal carcinoma in-situ (DCIS), is primarily diagnosed by imaging because it is usually clinically occult [16]. DCIS was previously an uncommonly identified breast lesion, now it accounts for approximately 20 percent of newly diagnosed breast cancer cases [17]. As the detection rate increased, there has also been increased discussion and controversy [18]. Because of the heterogenous nature of DCIS, the disease process is in part not well understood [19]. Although it sometimes presents as a nonaggressive occult lesion, untreated DCIS may progress into an aggressive, invasive cancer [20, 21].
El Sayed et al, found that underestimation rate of malignancy associated with B3 lesions is 19.1% [14] and Brennan meta-analysis showed that approximately one in four DCIS diagnoses by CNB represents understaged, invasive breast cancer [22].
Preoperative variables significantly associated with understaging include: Biopsy device and guidance method; size; grade; mammographic features; and palpability [22].
Therefore, we focused on lesions of unknown malignant potential and in-situ carcinomas in our single-center study. This paper will elucidate the concordance rate between tissue biopsies and postoperative histopathology over the course of 10 years. Imaging and pathological findings of the biopsies are concordant when the pathology results adequately explain the imaging features. If the pathological results do not adequately explain the imaging features the two are considered discordant [7].
Materials and methods
This retrospective study was performed after approval from the Ethics committee of Hannover Medical School. Given the retrospective nature of the study and data anonymization additional consent was waived by the ethics committee. Written informed consent was obtained from each patient before the biopsy was performed. Our retrospective study included 2,029 consecutive biopsies for patients who underwent mammograms or ultrasounds at our Hospital from January 2006 to December 2015.
Mammograms were done using a Mammomat® 3000 Nova (Siemens Healthcare, Erlangen, Germany), combined with a Fuji FCR 5000 MA reader (Fuji Medical Systems, Tokyo, Japan) from 2006 to 2010; and a flat-panel mammography with Mammomat Inspiration (Siemens Healthcare, Erlangen, Germany) from 2011 to 2015. All CNBs were performed using a coaxial, 14-gauge cutting needle with 15 mm or 22 mm penetration depths (Bard® MAGNUM® Biopsy System) by freehand sonography, using an Elegra scanner in 2006 (Siemens Healthcare, Erlangen, Germany); a LogiQ S6 scanner from 2007 to 2012 (GE Healthcare, Chicago); and an Acuson S2000 scanner from 2013 to 2015 (Siemens Healthcare, Erlangen, Germany). From 2006 to 2010 all VABs were performed using a 10-guage needle (VACORA® Breast Biopsy System, Bard®), under stereotactic guidance using mammography. From 2011 to 2015, VABs were done using 8-guage needle (Mammotome ST Biopsy Device) and a Mammotest table (Siemens Healthcare, Erlangen, Germany).
For each case, we collected the following data: age, BI-RADS®; guidance; histopathological biopsy results; B-category; DCIS nuclear grade, re-biopsy rate and postoperative histopathology results in B3 and B5a cases from the biopsy.
We specially focused on the concordance rate of the biopsy results compared to postoperative histopathology for patients with B3 and B5a category results in their biopsies. A review of the diagnostic mammograms and ultrasounds of the underestimated lesions in both categories was also done.
Statistical analysis
The data was analyzed using the IBM SPSS software package, V. 20.0. (Armonk, NY: IBM Corp). Kolmogorov-Smirnov, Shapiro and D’agstino tests were used to verify the normality of variable distribution. Comparisons between groups for categorical variables were assessed using chi-square test (Fisher’s exact test). Significance of the obtained results was documented at the 5 percent level.
Results
A total of 301 Vacuum assisted biopsies were performed under stereotactic guidance and 1728 core needle biopsies under ultrasound guidance were performed. Distribution of the B-categories, age and guidance are summarized in Table 1.
Seventy-three lesions were re-biopsied due to discordance between imaging and histopathological results of the VAB/CNB biopsies. From the 73 biopsies, 10 lesions histopathology results changed from B2 to B5b,1 lesion changed from B2 to B5a, 4 changed from B1 to B2 and 58 lesions did not change with a B2 result in both biopsies. B4 category was not included because those were only found in preliminary pathology reports of 4 cases which was categorized as B5a in the final histopathology report of the biopsy.
For the lesions with uncertain malignant potential (B3) and in-situ carcinoma (B5a) with CNB or VAB histopathology, a comparison to postoperative histopathology was done to show the concordance rate.
In the B3 category, 72 of 91 patients underwent surgical excision in our hospital. From the 19 non operated patients 12 had mammogram or ultrasound follow-ups for at least one year with no radiologic changes requiring a re-biopsy or surgical excision. Seven patients did not come for follow-up after the biopsy result.
Concordance between CNB/VAB and postoperative histopathology for B3 was found in 83.3 percent (n = 60/72 patients) cases, and discordance was documented in 16.7 percent (n = 12/72 patients) of cases. Three patients had two lesions, i.e. a total of 75 lesions. The 12 cases that were discordant with histopathology were upgraded as follows: Eight patients with DCIS (B5a) and four with invasive breast cancer (B5b). Table 2 summarizes the discordant cases regarding B3 lesions in CNB/VAB histopathology, compared to postoperative histopathology.
The most frequently excised lesion in the B3 subgroups was papillary lesion (50.7 percent), followed by atypical ductal hyperplasia (20 percent), flat epithelial atypia (12 percent), lobular intraepithelial neoplasia (8 percent), radial scar (5.3 percent), and phyllodes tumor (4 percent). Table 3 summarizes the frequency of the different B3 lesions from the biopsies and the rate of malignant diagnosis after excision.
From the underestimated lesions in B3 category in our study, 83.3 percent (n = 10/12) of the lesions were identified on mammograms, 66.6 percent (n = 8/12) were identified on ultrasound and 50 percent (n = 6/12) identified on both.
On the mammograms 41.6 percent showed a mass (n = 5/12), 50 percent microcalcifications (n = 6/12) and 25 percent architectural distortion (n = 3/12). On the Ultrasounds 50 percent showed a mass (n = 6/12), 16.7 percent architectural distortion(n = 2/12) and 8.3 percent a hypervascular area (n = 1/12). From the 38 papillary lesions excised we had 32 intraductal papillomas without atypia (associated for example, with columnar metaplasia, sclerosing adenosis or usual ductal hyperplasia), 2 intraductal papillomas with atypia, 3 intraductal papillomas associated with ADH and one with multiple peripheral intraductal papillomas. The upgraded papillary lesions (n = 6) presented 3 times as a mass forming lesion, 1 time as a hypervascular mass, 1 time with calcification, and 1 time as architectural disturbance.
In the B5a category, 101 of 115 patients underwent surgeries in our hospital (14 patients with DCIS in CNB/VAB, with no postoperative histopathology report in our records). Concordance rate was 80.2 percent (n = 81) and discordance rate was 19.8 percent (n = 20). High grade DCIS was recorded in 68 cases, from those 17 upgraded to invasive breast cancer.
Intermediate grade DCIS was recorded in 19 cases, from those 3 upgraded to invasive breast cancer. Low grade DCIS was recorded in 14 cases, from those non upgraded to invasive breast cancer.
The upgraded invasive carcinoma types were as follows: Eleven cases with invasive breast carcinoma of no-special type (NST); two cases with invasive lobular carcinoma; two cases with micro-invasion; one case with invasive lobular carcinoma and Paget´s disease of the nipple; one case with invasive breast carcinoma of no-special type (NST) and mucinous carcinoma; one case with tubular carcinoma; one case with papillary carcinoma; and one case with poorly differentiated carcinoma. The discordant cases from the B5a category are summarized in Table 4.
From the underestimated lesions in B5a category in our study, 85 percent (n = 17/20) of the lesions were identified on mammograms, 55 percent (n = 11/20) were identified on ultrasound and 40 percent (n = 8/20) identified on both.
On the mammograms 25 percent showed a mass (n = 5/20), 60 percent microcalcifications (n = 12/20), 5 percent architectural distortion(n = 1/20). On the Ultrasounds 50 percent showed a mass (n = 10/20), 5 percent a hypervascular area (n = 1/20) and none showed architectural distortion.
The biopsy needle size was documented for all lesions from the B3 and B5a category operated in our hospital to show the underestimation rates in each of the 8G, 10G and 14G needles used. There was no significant difference regarding smaller needle diameter and underestimation of malignancy, because of the overall small number of patients in both B-categories. Table 5 shows the results.
The most frequent histological diagnosis in the B2 category was fibroadenoma (29.9 percent), followed by Fibrous-, fibrocystic change (24.9 percent), sclerosing adenosis (16.1 percent), mastitis (7.4 percent), fat necrosis (7.3 percent), usual ductal hyperplasia (5 percent), simple cyst (4.7 percent), abscess (1.2 percent), and then other lesions (3.5 percent) such as lymph node, hematoma, pseudocyst and lipoma.
The most frequent histological diagnosis in the B5b category was invasive breast carcinoma of no-special type (87 percent), followed by lobular invasive carcinoma (9.7 percent), mucinous carcinoma (2.5 percent), tubular carcinoma (0.5 percent), and then other carcinomas (0.3 percent).
Radiological/histological correlation
This was done using BI-RADS and B-category of the biopsy, the results are summarized in Table 6. Then we also calculated the results for the underestimated lesions and its effect on this correlation.
In the BI-RADS 4a Category 547 lesions had B2 and B3 results in the biopsy result, meaning 92.4 percent true negative while 45 had B5a and B5b in the biopsy result, i.e. 7.6 percent false negative. This result was not changed when compared to the postoperative histopathology.
In the BI-RADS 4b Category 366 lesions had B2 and B3 results in the biopsy result, meaning 48.2 percent false positive while 393 had B5a and B5b in the biopsy result, i.e. 51.8 percent true positive. This result changed when compared to the postoperative histopathology because of the upgraded B3 lesions which were primary as BI-RADS 4b reported (5 cases), so the false positive decreased to 47.6 percent and the true positive increased to 52.4 percent.
In the BI-RADS 4c Category 12 lesions had B2 and B3 results in the biopsy result, meaning 8.8 percent false positive while 124 had B5a and B5b in the biopsy result, i.e. 91.2 percent true positive. This result was not changed when compared to the postoperative histopathology because none of the upgraded lesions was primary as BI-RADS 4c reported.
In the BI-RADS 5 Category 21 lesions had B2 and B3 results in the biopsy result, meaning 3.9 percent false positive while 516 had B5a and B5b in the biopsy result, i.e. 96.1 percent true positive.
This result changed when compared to the postoperative histopathology because of the upgrade B3 lesions which were primary as BI-RADS 5 reported (7 cases), so the false positive decreases to 2.6 percent and the true positive increased to 97.4 percent.
For the lesions which were assigned BI-RADS 4c (9 cases) and 5 (13 cases) with B2-category in the histopathology result, a re-biopsy was done for 2/9 cases in the BIRADS 4c and for 4/13 cases in the BIRADS 5 with no change of the histopathology result. A re-biopsy for 2/13 cases was recommended but it was declined from the patient with no further follow-ups in our records. Follow-ups for at least 12 months were done in 7/9 and 7/13 cases from both categories with no radiological change requiring re-biopsy.
Discussion
Most previous studies originated from mammography screening programs, limited to an age range from 50–70 years. However, in our single-center study, the age ranged from16 to 96.5 years in all different categories.
In our study, B3 lesions comprised 4.5 percent of the total biopsies (n = 2,029). In one of the largest screening studies, El-Sayed et al. found that B3 lesions comprised 5 percent of all CNBs [14]. In agreement with El-Sayed et al., our underestimation rate of malignancy was 16.7 percent, compared to El-Sayed et al.’s 19.1 percent [14]. Of those, our underestimation rate of invasive lesions was 33.3 percent, compared to 37.7 percent [14], and our underestimation rate of non-invasive lesions was 66.7 percent, compared to 62.3 percent [14].
In agreement with Hoffmann et al., there was no significant difference between the B3 subgroups and malignant diagnosis after excision [5]. Timpe et al. also found that the overall underestimation rate of malignancy for B3 lesions was 24.3 percent, with a positive predictive value of 0.30 for atypical epithelial proliferation of ductal type (AEDPT). They also found an underestimation malignancy rate of 0.11 for papillary lesions, and no under-estimation malignancy rate for radial scar and flat epithelial atypia lesions [23].
Weigel et al. found that the positive predictive value was 0.28 for malignancy in the B3 category, 0.40 for atypical epithelial ductal proliferation (which was statistically significant compared to other subgroups), 0.08 for papillary lesions, and 0.20 for radial scars [24]. The statistical significance for atypical epithelial proliferation of ductal type (AEDPT) compared to other subgroups in this study, was due to the percentage of the AEDPT lesions from total B3 lesions; 51.6 percent (n = 47/91). In our study the atypical ductal hyperplasia was only 20 percent from all B3 lesions (n = 15/75). The frequency of papillary lesion in our cohort was 50.6 percent and 20 percent for atypical ductal hyperplasia, compared to El-Sayed et al.’s respective findings of 24 percent and 36 percent [25]. The difference in the order of the two most frequent lesions in our study is most probably because our cohort was not confined to a specific age group.
Our results regarding the B3 subcategories, may be different from some previous studies, but the positive predictive value for malignancy for the B3 category is very consistent and the positive predictive value for malignancy for ADH was the highest, although it was not statistically significant.
The B5a lesions comprised 5.6 percent from all biopsied lesions and 10.6 percent from all malignant lesions in our study. Weigel et al.’s screening program found that 82.3 percent (n = 5,082) of their patients had invasive breast cancers, 17.4 percent (n = 1,074) had DCIS, and 0.3 percent (n = 16) had LCIS [26]. In agreement with Weigel et al., regarding nuclear grade distribution [26], the percentage of high-grade, in-situ ductal carcinomas in our study was 65.2 percent, compared to 40.2 percent in Weigel et al. Moreover, 21.7 percent and 37.3 percent were intermediate grade in our study and Weigel et al.’s, respectively. Furthermore, 13.1 percent and 17.2 percent were low grade in our study and Weigel et al.’s, respectively.
Most ductal carcinoma in-situ lesions found at mammography present as microcalcifications, with approximately 75 percent of lesions presenting only as calcifications [27]. Up to 23 percent of DCIS may present as a mass or asymmetry, and approximately 12 percent are associated with a palpable abnormality [27, 28]. Our study showed that 75.6 percent of in-situ ductal carcinomas were biopsied under stereotactic-guidance and our results were consistent with previous literature.
There were several limitations to our study. First, we used two different mammography systems–digital luminescence mammography until 2010, and then flat panel mammography after 2010. Second, stereotactic guidance before 2011 was done using mammography, with patients seated. After 2011, we used a Mammotest table with patients in a prone position. In some cases, posteriorly located lesions can be challenging to biopsy in the prone position leading to technical failure. However, Wunderbaldinger found that there was no significant differences regarding the patient position in large core biopsy [29].
Third, different needle sizes (8-, 10-gauge) were used for VABs, and 14-gauge needles were used for CNBs. Previous studies found that malignancy underestimation rates for high-risk lesions and DCIS using 8-gauge needles ranged from 0 percent to 17 percent. However, rates ranged from 3 percent to 25 percent with 11-gauge needle [30–33]. This was consistent with our results shown in Table 3. Finally, ultrasound guidance for CNBs was done with three different ultrasound scanners. The latter two had a tissue harmonic imaging mode, providing sometimes the possibility for better visualization of the different lesions especially those with cystic or fatty parts.
Conclusion
Our concordance rate for B3 (83.3 percent) and B5a (80.2 percent) lesions in the biopsies to postoperative histopathology matching to previously published literature. Surgical excision is our recommendation for lesions biopsied with a B3 category in the histopathology and a BIRADS category of (4b, 4c and 5). The PPVs for malignancy of B3 lesions showed no statistical significance between subgroups. Also, the nuclear grade of DCIS was not statistically significant in terms of upgrade into invasive breast cancer.
References
- 1. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–87. pmid:30100160
- 2. Hartmann LC, Degnim AC, Santen RJ, Dupont WD, Ghosh K. Atypical hyperplasia of the breast—risk assessment and management options. N Engl J Med. 2015;372(1):78–89. pmid:25551530
- 3.
D'Orsi CJ. ACR BI-RADS atlas: breast imaging reporting and data system: American College of Radiology; 2013.
- 4. Lee A, Anderson N, Carder P, Cooke J, Deb R, Ellis IO. Guidelines for non-operative diagnostic procedures and reporting in breast cancer screening. 2016:18–22.
- 5. Hoffmann O, Stamatis GA, Bittner AK, Arnold G, Schnabel R, Kruger K, et al. B3-lesions of the breast and cancer risk—an analysis of mammography screening patients. Mol Clin Oncol. 2016;4(5):705–8. pmid:27123266
- 6. Lee AH, Denley HE, Pinder SE, Ellis IO, Elston CW, Vujovic P, et al. Excision biopsy findings of patients with breast needle core biopsies reported as suspicious of malignancy (B4) or lesion of uncertain malignant potential (B3). Histopathology. 2003;42(4):331–6. pmid:12653944
- 7. Liberman L. Clinical management issues in percutaneous core breast biopsy. Radiol Clin North Am. 2000;38(4):791–807. pmid:10943278
- 8. Rakha EA, Lee AH, Jenkins JA, Murphy AE, Hamilton LJ, Ellis IO. Characterization and outcome of breast needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. Int J Cancer. 2011;129(6):1417–24. pmid:21128240
- 9. Houssami N, Ciatto S, Bilous M, Vezzosi V, Bianchi S. Borderline breast core needle histology: predictive values for malignancy in lesions of uncertain malignant potential (B3). Br J Cancer. 2007;96(8):1253–7. pmid:17438578
- 10. Andreu FJ, Sáez A, Sentís M, Rey M, Fernández S, Dinarès C, et al. Breast core biopsy reporting categories—An internal validation in a series of 3054 consecutive lesions. Breast. 2007;16(1):94–101. pmid:16982194
- 11. Dillon MF, McDermott EW, Hill AD, O'Doherty A, O'Higgins N, Quinn CM. Predictive value of breast lesions of "uncertain malignant potential" and "suspicious for malignancy" determined by needle core biopsy. Ann Surg Oncol. 2007;14(2):704–11. pmid:17151788
- 12. Maclean GM, Courtney SP, Umeh H, Sanjeev S, McCormick C, Smith BM. Is mode of presentation of B3 breast core biopsies (screen-detected or symptomatic) a distinguishing factor in the final histopathologic result or risk of diagnosis of malignancy? World J Surg. 2013;37(11):2607–12. pmid:23963348
- 13. Richter-Ehrenstein C, Maak K, Röger S, Ehrenstein T. Lesions of "uncertain malignant potential" in the breast (B3) identified with mammography screening. BMC Cancer. 2018;18(1):829. pmid:30115017
- 14. El-Sayed ME, Rakha EA, Reed J, Lee AH, Evans AJ, Ellis IO. Audit of performance of needle core biopsy diagnoses of screen detected breast lesions. Eur J Cancer. 2008;44(17):2580–6. pmid:18632261
- 15. Weigel S, Decker T, Korsching E, Biesheuvel C, Wostmann A, Bocker W, et al. Minimal invasive biopsy results of "uncertain malignant potential" in digital mammography screening: high prevalence but also high predictive value for malignancy. Rofo. 2011;183(8):743–8. pmid:21506072
- 16. Parikh U, Chhor CM, Mercado CL. Ductal Carcinoma In Situ: The Whole Truth. AJR Am J Roentgenol. 2018;210(2):246–55. pmid:29045181
- 17.
(AFHSC) AFHSC. Incident diagnoses of breast cancer, active component service women, U.S. Armed Forces, 2000–2012. MSMR. 2013;20(9):25–7.
- 18. Barrio AV, Van Zee KJ. Controversies in the Treatment of Ductal Carcinoma in Situ. Annu Rev Med. 2017;68:197–211. pmid:28099081
- 19. Park TS, Hwang ES. Current Trends in the Management of Ductal Carcinoma In Situ. Oncology (Williston Park). 2016;30(9):823–31. pmid:27633413
- 20. Sanders ME, Schuyler PA, Dupont WD, Page DL. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005;103(12):2481–4. pmid:15884091
- 21. Collins LC, Tamimi RM, Baer HJ, Connolly JL, Colditz GA, Schnitt SJ. Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy: results from the Nurses' Health Study. Cancer. 2005;103(9):1778–84. pmid:15770688
- 22. Brennan ME, Turner RM, Ciatto S, Marinovich ML, French JR, Macaskill P, et al. Ductal carcinoma in situ at core-needle biopsy: meta-analysis of underestimation and predictors of invasive breast cancer. Radiology. 2011;260(1):119–28. pmid:21493791
- 23. Timpe L, Berkemeyer S, Puesken M, Tio J, Heindel W, Weigel S. Rates of presurgical underestimation of breast cancer after standardized assessment of breast calcifications. Rofo. 2015;187(6):445–9. pmid:25877994
- 24. Weigel S, Decker T, Korsching E, Biesheuvel C, Wöstmann A, Böcker W, et al. Minimal invasive biopsy results of "uncertain malignant potential" in digital mammography screening: high prevalence but also high predictive value for malignancy. Rofo. 2011;183(8):743–8. pmid:21506072
- 25. El-Sayed ME, Rakha EA, Reed J, Lee AH, Evans AJ, Ellis IO. Predictive value of needle core biopsy diagnoses of lesions of uncertain malignant potential (B3) in abnormalities detected by mammographic screening. Histopathology. 2008;53(6):650–7. pmid:19076681
- 26. Weigel S, Heindel W, Heidinger O, Berkemeyer S, Hense HW. Digital mammography screening: association between detection rate and nuclear grade of ductal carcinoma in situ. Radiology. 2014;271(1):38–44. pmid:24475843
- 27. Barreau B, de Mascarel I, Feuga C, MacGrogan G, Dilhuydy MH, Picot V, et al. Mammography of ductal carcinoma in situ of the breast: review of 909 cases with radiographic-pathologic correlations. Eur J Radiol. 2005;54(1):55–61. pmid:15797293
- 28. Ikeda DM, Andersson I. Ductal carcinoma in situ: atypical mammographic appearances. Radiology. 1989;172(3):661–6. pmid:2549563
- 29. Wunderbaldinger P, Wolf G, Turetschek K, Helbich TH. Comparison of sitting versus prone position for stereotactic large-core breast biopsy in surgically proven lesions. AJR Am J Roentgenol. 2002;178(5):1221–5. pmid:11959735
- 30. Ruggirello I, Nori J, Desideri I, Saieva C, Giannotti E, Bicchierai G, et al. Stereotactic vacuum-assisted breast biopsy: Comparison between 11- and 8-gauge needles. Eur J Surg Oncol. 2017;43(12):2257–60. pmid:29042074
- 31. Diebold T, Hahn T, Solbach C, Rody A, Balzer JO, Hansmann ML, et al. Evaluation of the stereotactic 8G vacuum-assisted breast biopsy in the histologic evaluation of suspicious mammography findings (BI-RADS IV). Invest Radiol. 2005;40(7):465–71. pmid:15973139
- 32. Brem RF, Schoonjans JM, Goodman SN, Nolten A, Askin FB, Gatewood OM. Nonpalpable breast cancer: percutaneous diagnosis with 11- and 8-gauge stereotactic vacuum-assisted biopsy devices. Radiology. 2001;219(3):793–6. pmid:11376271
- 33. Venkataraman S, Dialani V, Gilmore HL, Mehta TS. Stereotactic core biopsy: Comparison of 11 gauge with 8 gauge vacuum assisted breast biopsy. Eur J Radiol. 2012;81(10):2613–9. pmid:22127375